Desvenlafaxine succinate: A new serotonin
and norepinephrine reuptake inhibitor

by
Deecher DC, Beyer CE, Johnston G, Bray J,
Shah S, Abou-Gharbia M, Andree TH.
Women's Health & Musculoskeletal Biology,
Wyeth Research, N3164, 500 Arcola Rd.,
Collegeville, PA 19426, USA.
deeched@wyeth.com
J Pharmacol Exp Ther. 2006 Aug;318(2):657-65.


ABSTRACT

The purpose of this study was to characterize a new chemical entity, desvenlafaxine succinate (DVS). DVS is a novel salt form of the isolated major active metabolite of venlafaxine. Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively. DVS showed weak binding affinity (62% inhibition at 100 microM) at the human dopamine (DA) transporter. Inhibition of [3H]5-HT or [3H]NE uptake by DVS for the hSERT or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively. DVS (10 microM), examined at a large number of nontransporter targets, showed no significant activity. DVS (30 mg/kg orally) rapidly penetrated the male rat brain and hypothalamus. DVS (30 mg/kg orally) significantly increased extracellular NE levels compared with baseline in the male rat hypothalamus but had no effect on DA levels using microdialysis. To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a 5-HT(1A) antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally). 5-HT increased 78% compared with baseline with no additional increase in NE or DA levels. In conclusion, DVS is a new 5-HT and NE reuptake inhibitor in vitro and in vivo that demonstrates good brain-to-plasma ratios, suggesting utility in a variety of central nervous system-related disorders.
Options
Desvenlafaxine
Venlafaxine v SSRIs
Venlafaxine compared
Venlafaxine v fluoxetine
High-dose venlafaxine XL
Venlafaxine pharmacology
Venlafaxine plus bupropion
Venlafaxine and depression
Venlafaxine and neuropeptides
Venlafaxine and major depression
Venlafaxine for depressive cocaine users
Venlafaxine (Effexor) v clomipramine for OCD
Venlafaxine for treatment-resistant depression
Venlafaxine, emotional processing and the brain
Trial of desvenlafaxine (Pristiq) to treat major depression
Depression treated with different formulations of venlafaxine
Desvenlafaxine (Pristiq) to treat menopausal vasomotor symptoms
February 2008: FDA licenses antidepressant desvenlafaxine (Pristiq)


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family